CML Advocates Network

For Chronic Myeloid Leukemia Patient Group Advocates

CML Advocates Network, January 2020

Our CML clinical trials data-base now lists 54 studies worldwide

Our clinical trials registry currently lists 54 studies:
  • 32 CML studies actively recruiting patients, including
  • 2 paediatric trials
  • 7 treatment-free remission trials
  • 20 studies that are no longer recruiting
We are pleased to share new trials from many countries worldwide including:
  • INCB84344-102, actively recruiting in Spain and Belgium
  • TIPI and PONAZA, France
  • RT51KRI03, South Korea
  • RERISE China, China
  • ENDURE, France and Germany.
For a number of trials (KISS, PONS, ASCEMBL, ASC4MORE, CALLS, CLR_15_03), new sites were opened in 24 countries.
Check out our CML clinical trials registry

CML was featured at during the "Best of #ASH19 session" 

During the American Society of Hematology Congress 2019, the Chronic Myeloid Leukemia was featured at during the final "Best of ASH" session with this study on the use of Asciminib + Ponatinib combination to overcome resistance:

"Combining the Allosteric ABL1 Inhibitor Asciminib (ABL001) with Ponatinib Suppresses Emergence of and Restores Efficacy Against Highly Resistant BCR-ABL1 Compound Mutants"

More reports on the best of CML at #ASH19 are coming soon, stay tuned!
Check out the full Abstract here

For the first time, the 18th CML Horizons will be held outside of Europe and will take us to Central America in Costa Rica.
The CML Horizons conference is dedicated to the development of our members as patient advocates and this year we will be discussing topics such as: 
  • Improving access & the impact of policy.
  • CML Treatment.
  • Why our work is not done.
  • TFR: ensuring patients are not at risk.
  • Living with CML.
  • Interactive regional workshops. 
Already registered? Stay up to date via our Facebook Event HERE.
Register Now

The CML Advocates Network Steering Committee meeting in Frankfurt, Germany

On January 18 and 19 2020, the CML Advocates Network Steering Committee and management team came together to work on the network's strategy as well as ongoing and new projects for the global CML patient advocacy community.
Two days full of interesting discussions took place on CML-related hot topics, project management planning, strategic goals and questions addressing many future challenges.
To know more about our Steering Committee please, visit "About the Network". 

CML Advocates Network
Copyright © 2019 – All rights reserved.

Our mailing address is:

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.



Zagreb, HR

Hrvatska udruga leukemija i limfomi
predsjednik Dražen Vincek
Trg hrvatskih velikana 2/ll
10 000 Zagreb
GSM: +385 (0)91 4873 561
TEL: +385 (0)1 4873 561
Web adresa:
IBAN: HR 36 2340 0091 1100 4711 4

Važni datumi


Health through Knowledge

Klasa optimist

Istaknuti sponzori HULL-a